The success of chemotherapy for metastatic germ cell tumours has led to them being described as the model of a curable malignancy. However, 20-30% of patients with metastatic disease relapse after first-line chemotherapy, and for them the prognosis is poor Motzer et al., 1991; Pizzocaro et al., 1992a; Horwich et al., 1993a : Josefsen et al., 1993 . High-risk patients can often be identified from the extent of disease at presentation. Of 7% patients contributing to prognostic model analyses at the Memorial Hospital, 73% were predicted to be in remission 1 year after chemotherapy. This figure fell to 30% in patients identified as being in a poor-risk category (Bajorin et al., 1994) . Similarly, in an Eastern Cooperative Oncology Group (ECOG) chemotherapy trial based on patients categorised as having advanced disease on the Indiana University classification, less than 50% remained continuously disease free . These figures indicate a substantial need to improve the efficacy of chemotherapy in some subgroups of patients with metastatic germ cell tumours, and increasing the dose intensity of conventional agents has yet to have a demonstrable impact on their survival (Nichols et al., 1991; Droz et al., 1992) . Therefore, there is a continued need for drug development in germ cell tumours, and current examples include the phase II investigation of Taxol (Motzer et al., 1994) as well as the observations reported by Pera et al. (1995) in this issue, both of which merit more extensive investigation. Even patients who have failed on previous chemotherapy usually retain an excellent performance status and good bone marrow function, and the poor prognosis justifies innovative approaches to their treatment (Horwich et al., 1993b) .
One of the difficulties in evaluating results of new approaches to the salvage treatment of germ cell tumours is the heterogeneity of patients at this phase of the illness. Relevant factors which might influence prognosis include the extent of disease at presentation, the details and response to primary chemotherapy, together with residual organ tolerance, especially renal function, the disease-free interval before progression and the extent of disease at relapse (Horwich et al., 1993a; Josefsen et al., 1993) . Patients referred to a specialty centre may have previously suffered a number of recurrences after a range of conventional chemotherapy approaches, whereas those treated initially at the specialty centre may enter an experimental programme after their first chemotherapy course, i.e. after only four prior chemotherapy cycles (Hutter et al., 1994) . In a series of 105 patients treated for relapse at the Royal Marsden Hospital between 1980 and 1988 (Horwich et al., 1993b Fewer of these patients had high markers (alphafetoprotein > 1000 units 1-1 or human chonronic gonadotrophin >10,000 units -') at the time of relapse than at original presentation, namely 21% vs 37% respectively. The interval between the end of initial chemotherapy and relapse was between 0 and 8 months in 30 patients, between 8 and 15 months in 48 patients and more than 15 months in 27 patients. Of the total series, the 3 year survival probability from time of beginning salvage chemotherapy was 30%. However, a multivariate analysis of survival showed a significantly higher risk of mortality in those with a diseasefree interval of less than 8 months and in those with very large volume disease at relapse. The analysis allowed subgroups to be identified whose prognosis on standard-dose chemotherapy was extremely poor with a 3 year survival probability of less than 10%, while other subgroups had a 3 year survival probability of up to 70%, suggesting that highrisk salvage therapies might be employed on a selective basis. Similarly, a series of 55 patients reported from Norway had a disease-free survival from the time of salvage chemotherapy of 27% at 5 years. A better prognosis was defined by complete response to primary treatment lasting more than 6 months, and this subgroup had a 45% 5 year disease-free survival probability (Josefsen et al., 1993) .
Therapeutic approaches to be considered in salvage therapy include the use of alternative drug combinations, the use of local treatment modalities such as surgery or radiation therapy and the role of high-dose chemotherapy with stem cell support. The appropriate deployment of these options is influenced by the primary chemotherapy and initial response but also by current treatment tolerance and the extent of disease at relapse. The likelihood of the relapse being associated with a degree of drug resistance encourages an aggressive surgical approach for disease which is relatively localised although, unless the relapse is both isolated and indolent, salvage therapy should be initiated with chemotherapy. Assessments should include the glomerular filtration rate in those who have previously had cisplatin and lung function tests in those who have had bleomycin. Staging should include CT or MRI scan of the brain (Josefsen et al., 1993; Raina et al., 1993) .
There is some evidence that alternative standard chemotherapy regimens can cure a proportion of patients in whom primary chemotherapy has failed. Etoposide showed significant activity in patients who had relapsed after the combination of platinum, vinblastine and bleomycin (PVB) (Fitzharris et al., 1980) , and the combination of etoposide and cisplatin was curative in approximately one-quarter of patients (Bosl et al., 1985; Hainsworth et al., 1985) . It was more difficult to salvage patients whose primary chemotherapy contained etoposide and cisplatin (Horwich and Peckham, 1984) . However, ifosfamide was highly active in this context (Wheeler et al., 1986) (Cantwell et al., 1990; Miller and Einhorn, 1990 ). More recently, Taxol has been investigated in patients who had failed to respond to standard platinum therapies and shows promising activity (Motzer et al., 1994 (Fox et al., 1993) . Daily oral etoposide has been investigated in this role (Cooper et al., 1994) .
The relatively low success rate of salvage chemotherapy in patients who have failed to respond to etoposide-cisplatin combinations has led to preliminary evaluations of high-dose chemotherapy with autologous bone marrow transplant (ABMT) or, more recently, blood stem cell support. In view of the non-haematological toxicities of cisplatin, high-dose therapy is usually based on carboplatin, together with etoposide and either cyclophosphamide or ifosfamide. Trials of this approach were begun in Indiana University in 1986 using high-dose carboplatin and etoposide with ABMT. Of 32 patients registered for this study in the first 2 years, the chemotherapy consisted of etoposide 1200mgm-2 together with carboplatin in an escalating dose schedule from 900 mg m-2 to 2000 mg m-2. Seven patients died of treatment-related problems. However, there were eight complete remissions in a 42% response rate (Nichols et al., 1989) . More recent follow-up of the first 40 patients treated in this same study found that only six (15%) were alive and continuously disease free at a minimum of 36 months, though a further patient had died of acute myelogenous leukaemia while in remission 28 months after ABMT (Broun et al., 1992) . A recent review of high-dose chemotherapy suggested that the inclusion of either cyclophosphamide or ifosfamide in the high-dose regimen may increase the proportion of patients with a durable complete remission , and this was supported by multivariate analysis of a series from France (Droz et al., 1993) . The review included 272 patients reported since 1984 who had been treated with high-dose chemotherapy and ABMT for relapse of germ cell tumour after cisplatin chemotherapy. There were 80 complete responses (31%), but only 44 of these (17%) were durable, and in the same series there were 29 (11%) treatment-related deaths. However, excellent results have also been reported using only carboplatin and etoposide in the high-dose regimen (Broun et al., 1994) . The addition of an alkylating agent to the high-dose chemotherapy combination does not appear to increase treatment-related mortality (Siegert et al., 1991; Linkesch et al., 1993) . Careful patient selection associated with the use of growth factors and blood stem cells can reduce the toxicity.
At the Royal Marsden Hospital, our treatment approach for patients who have failed standard schedules of cisplatinbased chemotherapy is to undertake a 4 week course of intensive weekly induction based on bleomycin, vincristine and cisplatin (Horwich et al., 1993b) . Patients whose disease stabilised or responded to this went on to high-dose carboplatin and etoposide and, if the response continued, a second cycle of high-dose carboplatin and etoposide was administered 2-3 months later. The high-dose chemotherapy was supported by autologous bone marrow transplantation. Thirty-three patients were eligible for this treatment programme between 1991 and 1993, but three declined the highdose approach and, of the remaining 30, seven progressed during conventional dose induction chemotherapy (Lampe et al., 1995) . A fixed dose of etoposide at 1200mgm-2 was employed in each high-dose course. However, the carboplatin dose was based on renal function to achieve a desired serum concentration x time (Calvert et al., 1989) . The carboplatin dose was increased from 15 mg ml-' min to 40 mg mlV-min and, based on a range of toxicities, but especially gastrointestinal toxicity, it was recommended that further studies be pursued at a serum concentration x time of 30 mg mnl ' min. Eight of the 23 patients treated with high-dose chemotherapy are alive and in remission 6-32 months from start of salvage chemotherapy.
The range of results in patients whose salvage chemotherapy is based on high-dose chemotherapy, together with the heterogeneity of treated patients, has made it difficult to evaluate the true role of this approach. There is little doubt that some patients progressing on standard dose chemotherapy can achieve long-term complete remission using high-dose techniques, but a higher proportion of remissions are obtained in patients who remain sensitive to standard dose treatment, who have a limited extent of disease at relapse and whose initial treatment may have been less dose intensive (Barnett et al., 1991; Einhorn, 1994 
